← All trials
NCT05570058
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 8, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Apr 30, 2024
- First posted
- Oct 6, 2022
- Last posted
- Oct 6, 2022
- Enrollment
- 64
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Redx Pharma PlcLead sponsor
- Imperial College LondonOverall official - principal investigator
- Simbec-OrionCollaborator
- University of Southern CaliforniaOfficial
- Imperial College LondonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.